function in pediatric gliomas tend to be different from those present in adult tumors. We present a review of these mutations affecting the histone code and telomere length, highlighting their importance in prognosis and as targets for novel therapeutics in the treatment of diffuse gliomas. 
tightly coupled to DNA replication during S phase, replacement histones are expressed throughout the cell cycle and are deposited into nucleosomes in a replication-independent manner.
Histone 3.1 is the canonical histone 3 (H3) protein, encoded by ten genes of the HIST1 cluster on chromosome 6, including the HIST1H3B gene [4] . Histone 3.3 (H3.3) is a replacement histone, encoded by H3F3A or H3F3B, unique genes on chromosome 1 and 17 producing an identical amino acid sequence [5, 6] . H3.3 varies from H3.1 by five amino acids (codons 31, 87, 89, 90, and 96) with amino acid 31 being a serine of the H3.3 N-terminal tail that can be phosphorylated [6] . The incorporation of H3.3 into telomeric and pericentric chromatin is accomplished by ATRX-DAXX (alpha thalassemia/mental retardation syndrome X-linked and death-domain associated protein) chaperone protein complex, while HIRA (histone regulator A) deposits H3.3 into chromatin areas of active and suppressed genes [7] [8] [9] [10] .
Protectors of chromosomes and cellular longevity: telomeres
Telomeres provide the solution to the universal "end replication problem," which occurs in every cell due to inability to completely replicate chromosome ends [11] [12] [13] [14] . Telomere length can be maintained by the enzyme telomerase that contains a telomerase reverse transcriptase (TERT) catalytic component and an RNA template strand. While telomerase expression and activity is maintained within stem cells by epigenetic mechanisms, telomerase activity is minimal to undetectable in most somatic cells [12, 14, 15] . Two hotspot mutations in the promoter region of the TERT gene (chr.5: g.1,295,228C > T and g.1,295,250C > T) were first reported in 71% of sporadic melanomas [16, 17] , and have since been detected in numerous cancers [15] . These mutations create novel-binding sites for E-26 (ETS) transcription factors, specifically the GABP transcription factor that binds to the mutant promoter, resulting in increased TERT transcription [18] .
In the absence of telomerase activity, telomere length can be maintained by homologous recombination, a mechanism known as alternative lengthening of telomeres (ALT). ALT is utilized by approximately 5-15% of human cancers [19, 20] , and is associated with genetic inactivation or loss of expression of the histone H3.3 chaperone proteins ATRX and DAXX [20, 21] .
Mutations of histone genes and readers, writers, and erasers of the histone code in gliomas
Mutations in genes affecting the histone code and alterations of histone methylation status have been reported in several cancer types [2, [22] [23] [24] [25] [26] [27] [28] . However mutations directly affecting histone genes were originally described in gliomas [1, [29] [30] [31] , and have been subsequently found in chondroblastomas and giant cell tumors of bone [7, 32] . Tail mutations of histone H3 at amino acids 27 and 34 leading to K27M (lysine to methionine substitution at codon 27) and G34R/V (glycine to arginine or valine substitution at codon 34) were initially reported in 36% of non-brainstem pediatric high-grade gliomas, with 14% containing G34R/V mutations and 22% containing K27M mutations [30] (Table 1 ). H3.3 K27M mutation is also found in 70-80% of pediatric diffuse intrinsic pontine gliomas (DIPGs) [29, 30] (Fig. 2) , a tumor now classified as diffuse midline glioma, H3 K27M mutant, WHO grade IV. Mutations predominantly occur in the H3F3A gene encoding H3.3, but analogous K27M mutations are also found at lower frequency in histone 3.1 gene HIST1H3B. Histone H3.3 K27M and G34R/V mutations are mutually exclusive with each other, with analogous histone 3.1 mutations, and with IDH1/2 mutations [30, 31, 33] . H3 K27M mutations characterize diffuse midline gliomas arising in both pediatric and adult patients, while H3 G34R/V mutations are found in diffuse gliomas centered within the cerebral hemispheres arising predominantly in older pediatric patients [31] .
Diffuse midline astrocytomas containing somatic H3 K27M substitution mutations were initially reported within the thalamus, pons, and spinal cord of pediatric patients at an average age of 10 years and correlated with worse prognosis compared to patients with histone H3 wild-type tumors [1, [29] [30] [31] . The occurrence of H3 K27M mutations has now been expanded to additional midline locations including the third ventricle, hypothalamus, pineal region, and cerebellum [34] . While pontine K27M mutations are found in younger patients, K27M mutations have been increasingly recognized in diffuse midline gliomas of adolescents and adults, occurring in 52-58% of adult spinal cord, brainstem, and thalamic gliomas [35, 36] . Diffuse gliomas with K27M mutations have been reported in the thalamus and spinal cord with a median age of 24 years, and in Fig. 1 Illustration of the histone code that is disrupted by genetic alterations in pediatric and adult gliomas. The histone octamer is depicted as the protein core of the nucleosome, in relation to overall chromatin structure (top panel). The deposition of the histone variant H3.3 into nucleosomes at telomeres requires the ATRX-DAXX chromatin remodeling complex (middle panel). The N-terminal histone tail of H3.3 is shown (bottom panel), with emphasis on the K27 and G34 amino acid residues that are frequently mutated in diffuse gliomas. The K36 residue is also shown as it is a critical site of post-translational modification, affected by both G34R/V mutations and mutations in the K36 methyltransferase SETD2. Writers and erasers of the histone code are displayed including the enhancer of zeste homolog 2 (EZH2), the K27 methyltransferase catalytic subunit of the polycomb repressive complex 2 which is inhibited by K27M H3.3 mutation. EED and SUZ12 are other members of the polycomb repressive complex 2; while they are not commonly mutated in diffuse gliomas they are involved in tumorgenesis of other neoplasms such as malignant peripheral nerve sheath tumors [3] . Also shown is JMJD3, the K27 demethylase that is one potential target of therapeutic intervention for K27M mutant gliomas. The oncometabolite 2-HG (2-hydroxyglutarate), produced by mutant IDH1/2 enzymes, is shown inhibiting H3K27 demethylation. Other key histone acetyltransferases (CBP) and demethylases (KDM2A and UTX) are shown to demonstrate the complexity of histone code regulation at amino acid residues K27 and K36, although these enzymes are not frequently mutated in diffuse gliomas ◂ the pineal region of a 65-year-old patient [34] . In pediatric diffuse midline gliomas, K27M mutation status correlates with very poor prognosis regardless of histologic grade, whereas K27M mutation in thalamic gliomas of adult patients does not always correlate with worse prognosis [4, 29, 36, 37] . Diffuse midline glioma, H3 K27M mutant, is defined within the 2016 WHO Classification of Tumours of the Central Nervous Systems as a grade IV neoplasm even in the absence of high-grade histologic features.
ATRX or DAXX gene mutations have been reported to co-occur with K27M mutations, yet the frequency of cooccurrence is variable across studies with reported comutation rates of 30-60% [1, 38] . Variability in the coexistence of ATRX and K27M mutations may be explained by location specific differences. The co-mutation rate was recently reported as 75% in thalamic gliomas, 57% in spinal gliomas, and 8% in pontine gliomas [34] .
G34R/V histone H3 mutations are found in diffuse gliomas within the cerebral hemispheres, affect adolescents with a median age of 18, and portend a better prognosis compared to diffuse midline gliomas with H3 K27M mutation [1, 31] . ATRX mutations frequently occur with G34R/V histone mutations, with reported co-mutation rates ranging from 75 to 100% [1, 38] . Diffuse gliomas arising in the cerebral hemispheres can alternatively harbor mutations in SETD2, a methyltransferase specific to lysine-36 of the histone 3 tail, making the encoded SETD2 (SET domain containing 2) protein a histone code writer. SETD2 mutations have been reported in approximately 15% of pediatric high-grade diffuse gliomas in the cerebral hemispheres. SETD2 mutations often occurred in children above the age of 12 and had very frequent co-occurring ATRX mutations, with similar age range and co-mutation spectrum as G34R/V mutant gliomas [39] . Mutations in SETD2 were mutually exclusive with H3 G34R/V mutations in all gliomas studied to date.
Mutations affecting the histone code of diffuse gliomas include the following: (1) mutations of the histone tail that directly alter a post-translational modification site, exemplified by the K27M mutation, (2) mutations within the histone tail that are adjacent to and interfere with a posttranslational modification site, namely the G34R/V mutations, (3) mutations within enzymes or that affect enzymes involved in writing or erasing the histone code, such as SETD2 mutation or IDH1/2 mutation (Fig. 1 ). The heterozygous K27M mutation in histone H3 impairs methylation at position 27 by two mechanisms. Methionine does not undergo methylation; this substitution directly removes a methylation site from the histone tail. Additionally, the K27M-mutant histone 3.3 protein is a dominantnegative inhibitor of K27 methylation by sequestration of the PRC2 complex (polycomb repressive complex 2), which contains the EZH2 (enhancer of zeste) K27 methyltransferase. This results in decreased levels of tri-methylated lysine 27 of histone 3 (H3K27me3), a histone tail mark typically associated with silenced chromatin [33, 40] .
Diffuse gliomas with G34R/V and K27M mutations have distinct hypomethylated genomes, a finding most prominent in G34R/V mutations with particularly pronounced hypomethylation at chromosome ends [31, 33] . G34R/V and K27M mutations both show mutation-specific gene expression profiles, with distinctive expression patterns similar to those observed during normal brain development [1, 31, 33] . In particular G34R/V mutant gliomas have gene expression profiles resembling early embryonic and early to mid fetal stages of neocortical and striatum development, while K27M gliomas have gene expression profiles that resemble mid to late fetal stages of thalamic and striatum development [31] . Of note, the PRC2 complex that is inhibited by K27M mutation additionally plays a prominent role in the progression of neural precursor cell differentiation. PRC2 within neural precursor cells suppresses neuronal differentiation and promotes astrocytic differentiation [41] . While the exact cell of origin is unknown, K27M and G34R/V mutant gliomas are thought to have a different cell of origin due to their unique gene expression profiles and location predilections [31] . The mechanistic link between altered histone tail methylation, DNA hypomethylation, and altered gene expression is yet to be elucidated. While G34R/V mutations do not directly occur at a site of post-translation modification, they occur in close proximity to lysine 36 of the histone H3.3 tail, which can be mono-, di-, and tri-methylated or acetylated in association with transcriptionally active or silenced chromatin. As glycine is a small uncharged amino acid residue, substitution with arginine or valine likely alters the post-translational modifications that occur at lysine 36 through steric inhibition or conformational tail changes, thereby interfering with code writers, erasers, and readers [1, 7] . Decreased histone H3 K36 trimethylation (H3K36me3) is observed within nucleosomes that contain an H3.3 G34R/V mutated tail. Furthermore, diffuse gliomas in the cerebral hemispheres lacking histone H3 gene mutations but instead harboring inactivating SETD2 mutations also demonstrate a significant decrease in H3K36me3 levels [39, 40] .
Hotspot mutations affecting the IDH1 or IDH2 genes, encoding isocitrate dehydrogenase enzymes of the citric acid cycle, define the vast majority of lower grade diffuse gliomas and secondary glioblastomas arising in adults, but are only rarely seen in gliomas in young children. These IDH1/2 mutations also affect histone methylation, and in contrast to K27M and G34R/V mutations, are associated with DNA hypermethylation. The recurrent IDH1 R132H and IDH2 R172H substitution mutations cause a gain-offunction that results in production of the oncometabolite 2-HG (D-2-hydroxyglutarate), which inhibits a wide range of histone demethylases, including those involved in the demethylation of H3K4, H3K9, H3K27, and H3K79 [42] [43] [44] .
Mutations and other alterations in genes affecting telomere length in gliomas
Amongst diffuse gliomas in adult patients, TERT promoter mutations are seen in almost all tumors (88-98%) with codeletion of chromosomes 1p and 19q along with IDH1 or IDH2 mutation, the typical molecular profile of adult-type oligodendroglioma [45, 46] , which demonstrates better overall survival compared to other glioma molecular groups [47] and elevated TERT expression [48] . Additionally TERT promoter mutations have been reported in 58-83% of adult primary glioblastomas, with a lower prevalence in secondary glioblastomas (28%) [15, 45, 49] . In grade II-III adult diffuse gliomas without 1p and 19q co-deletion, only 15% have TERT promoter mutations [47] . TERT promoter mutations in adult primary glioblastoma are associated with worse prognosis [47, 50] . A high frequency of TERT promoter mutations (81%) have been reported in the gliosarcoma variant of glioblastoma [46] .
While TERT promoter mutations were originally reported in 11% (2/19) of primary pediatric glioblastomas [15] , a subsequent study found TERT promoter mutations in only 3% (1/32) of pediatric primary glioblastomas [46] . The single case in the second study was a non-canonical g.1,295,228C > A mutation that did not create a novel ETS transcription factor binding site [46] . In general, pediatric gliomas rarely have TERT promoter mutations; analysis of 373 pediatric nervous system tumors including 200 gliomas found only 7 TERT promoter mutations [46] . Although pediatric TERT promoter mutations are rare, a single study has reported TERT promoter hypermethylation in association with increased TERT expression in pediatric highgrade gliomas [51] . Aberrant TERT promoter methylation with increased TERT expression has been reported in other cancer types [52] [53] [54] . In adult gliomas TERT promoter mutation rather than promoter methylation is the predominant mechanism for TERT upregulation [55] . Although ATRX and TERT promoter mutations are usually mutually exclusive, supporting an equivalent selective advantage of mutations maintaining telomere length through either ALT or increased telomerase activity [15] , rare exceptions to this have been observed in adult gliomas [47, 48] .
Somatic mutations in ATRX and DAXX were initially identified in pancreatic neuroendocrine tumors [56] and were found to be highly associated with ALT [21] . ATRX or DAXX mutations are present in approximately 30% of pediatric glioblastomas, with mutation and loss of immunostaining occurring much more frequently in ATRX than DAXX, and ALT highly correlating with ATRX loss [1] . ALT in high-grade pediatric gliomas with TP53 mutation is associated with increased overall survival [57] . ATRX mutations have also been reported in 9% of DIPGs, but are not prevalent in pediatric low-grade gliomas [29, 58, 59] . ALT rarely occurred in pediatric low-grade gliomas [57] , an interesting finding due to the corresponding low prevalence of ATRX mutation. This is consistent with the concept that telomere maintenance is not a necessary component of pediatric low-grade gliomas. Lack of telomere maintenance in pediatric low-grade gliomas may explain the occurrence of growth arrest and the low rate of transformation to highgrade gliomas [60] .
While ATRX mutations in pediatric glioblastomas are associated with TP53 and histone H3 mutations [1, 57] , ATRX mutations in diffuse gliomas within adult patients are associated with concurrent TP53 and IDH1/2 mutations (Fig. 3) , occurring in greater than 90% of lower-grade diffuse astrocytomas and secondary glioblastoma in the context of IDH1/2 mutation with intact chromosomes 1p and 19q [48, 58] . In contrast, ATRX mutations are seen in 4-7% of primary glioblastomas with wild-type IDH1/2 alleles [21, 58, 61] . DAXX mutations are rare in adult lower-grade gliomas at less than 1% frequency [62] .
ALT is observed in pediatric high-grade astrocytomas (29%), DIPG (18%), adult high-grade (26%), and low-grade (27%) astrocytomas [57, 63] . ALT is highly associated with ATRX mutations in adult low-grade gliomas and in high-grade astrocytomas of children and adults [61, 63] . Accordingly there is interest in the role of ATRX in gliomagenesis, and the potential connection with histone mutations. In vitro studies in immortalized cell cultures have shown that ATRX loss by itself is not sufficient to produce ALT, suggesting that additional genetic and/or epigenetic changes are required [19, 20, 64] . This is in agreement with the existence of ATRX mutations in adult high-grade gliomas without ALT, although 80% of cases with ATRX mutation had ALT [63] . The notion that multiple steps are required for the development of ALT is supported by the low frequency at which it arises in immortalized cell lines, and the likely prerequisite mutations of both the G1/S and G2/M checkpoints to be permissive of the genomic instability and altered response to DNA damage seen with ALT. The G1/S checkpoint is frequently undermined by TP53 mutation in association with ATRX mutation and ALT. Functional deficiencies in the G2/M checkpoint have been observed in ALT cell lines, warranting investigation of specific mutations in G2/M checkpoint signaling in ALT [20, 57] .
ATRX localizes to telomeres during interphase [64] , and both ATRX and DAXX are required for the deposition of H3.3 at telomeres [8] . The ATRX-DAXX complex is also involved in chromatin remodeling, and can mobilize a histone 3.3 containing nucleosome along a DNA template [8] . The consequences of disrupted H3.3 heterochromatin insertion and altered chromatin remodeling are among the proposed mechanisms for the association of ATRX mutation and altered telomere length. Additionally ATRX is a histone code reader. The PHD domain of ATRX binds to histone 3 tails with lysine 9 tri-methylation (H3K9me3) in the absence of lysine 4 methylation, indicating that ATRX 
When ATRX is unable to bind to the histone 3 tail, it fails to localize to heterochromatin [65] . Mutations affecting the histone code could potentially disrupt the association with ATRX, even in the absence of an ATRX mutation. ATRX has also been shown to bind GC-rich tandem sequences of telomeres and euchromatin, with mutation of ATRX leading to dysregulation of GC-rich tandem repeat associated genes [66] . Therefore ATRX mutation could indirectly affect telomere length by altering expression of telomere homologous recombination regulatory elements [20] .
Histone methyltransferase or DNA methyltransferase knockout in mouse cell lines results in increased telomere length, suggesting that telomere length can be influenced by either altered histone methylation or altered DNA methylation [64, 67, 68] . This is intriguing since ATRX mutations and histone H3 gene mutations are independently associated with altered methylation of subtelomeric regions [69] and chromosome ends [31, 33] . Subtelomeric methylation changes could potentially be explained by similarity of ATRX's PHD domain to the DNMT3 (DNA methyltransferase 3) family of DNA methyltransferases [64, 69] , and cells deficient specifically in DNMT3 also have increased telomere length [68] .
Additionally, loss of ATRX is associated with abnormal retention of the telomere RNA transcript (TERRA) and replication protein A (RPA) at telomere ends after completion of DNA replication. This leads to prolonged recruitment of the protein kinase ATR (ataxia-telangiectasia mutated and Rad3 related) to telomere ends, a regulator of homologous recombination, promoting an environment for recombination outside of normal regulatory mechanisms [19] .
Ultimately a downstream consequence of ATRX mutation, when combined with other mutations or epigenetic changes, is highly likely to create an altered telomere chromatin environment that is more permissive of homologous recombination and resultant ALT. Lack of insertion of histone 3.3, changes to DNA and telomere methylation from ATRX mutation or histone H3 mutation, altered expression of homologous recombination regulatory elements, and retention of TERRA with prolonged recruitment of ATR are all currently proposed mechanisms for the development of ALT.
Therapeutic interventions targeting the histone code and telomere length in gliomas
Understanding the role of histone mutations and alterations of the histone code in gliomagenesis has led to the development of potentially targeted therapeutic interventions. In particular GSKJ4, a small molecule inhibitor of the histone H3 K27 demethylase JMJD3, resulted in decreased tumor cell viability and increased H3K27me3 levels in K27M glioma cell lines, and significantly extended survival of mice with K27M mutant glioma xenografts. In contrast, GSKJ4 has not shown activity in an H3F3A G34V mutant glioma cell line [70] . Panobinostat, a histone deacetylase inhibitor, resulted in decreased tumor cell viability in both K27M mutant glioma cell lines and in mice with K27M mutant glioma xenografts. Panobinostat treatment demonstrated a dose dependent increase in histone acetylation and in H3K27me3, which may be explained by reduced PRC2 inhibition secondary to increased histone tail acetylation [71, 72] . Combined use of GSKJ4 and panobinostat produced a synergistic reduction of tumor cell viability in K27M mutant glioma cell lines [71] .
Cancer cell lines with decreased H3K36me3 secondary to inactivating SETD2 mutation, silencing, or knockout are sensitive to WEE1 kinase inhibition [73] , creating the possibility of targeted intervention in diffuse gliomas with SETD2 or G34R/V mutations. WEE1 inhibition induces degradation of RRM2, a ribonucleotide reductase subunit involved in the formation of deoxyribonucleotides from ribonucleotides. H3K36 trimethylation normally induces transcription of RRM2, and reduced H3K36 methylation causes decreased levels of RRM2. In the setting of reduced H3K36 methylation, the effect of WEE1 inhibition on RRM2 degradation exacerbates already reduced RRM2 levels reaching a critical level of dNTP depletion that inhibits DNA replication and induces apoptosis [73] .
Additionally, gliomas with G34R/V mutations have been shown to upregulate MYCN, through altered genomic binding of the histone 3 tail at K36 [74] . Therefore PI3K/ mTOR inhibitors such as NVP-BEZ235, which result in MYCN degradation [75] , may potentially be therapeutic in G34R/V gliomas.
Inhibitors against mechanisms of telomere maintenance are in development. The telomerase inhibitor GRN163L (Imetelstat) is an oligonucleotide complementary to the telomerase RNA template, and has entered Phase II clinical trials for pediatric recurrent or refractory brain tumors [76, ClinicalTrials.gov NCT01836549] . Additionally inhibitors of the protein kinase ATR, a regulator of homologous recombination with prolonged recruitment to telomere ends in the setting of ATRX mutation, have been found to selectively induce death of cancer cells with ALT [19] .
Summary
Pediatric and adult gliomas contain genetic alterations that affect the histone code, most frequently seen by direct mutation of the histone H3 tail in pediatric gliomas and IDH1/2 mutation in adult gliomas. Histone H3 tail mutations are mutually exclusive with IDH1/2 mutations and both uniquely alter histone tail methylation. The K27M and G34R/V mutations are associated with decreased histone tail methylation and DNA hypomethylation, while IDH1/2 mutant gliomas correlate with DNA hypermethylation and 2-HG mediated inhibition of histone demethylation. The prevalence of IDH1/2 or histone H3 mutations within diffuse gliomas emphasizes the delicate balance of histone methylation and the functional importance of the histone code in gliomagenesis of both adults and children.
Mutations affecting telomere length are also distinctly different in pediatric and adult gliomas. TERT promoter mutations are frequently seen in adult primary glioblastomas and oligodendrogliomas but are extremely rare in pediatric gliomas. In contrast to the high frequency of ATRX mutations in adult lower-grade astrocytomas, ATRX mutations are not prevalent in pediatric low-grade gliomas. While some mechanism of telomere maintenance has been proposed as a requirement for gliomagenesis in adult gliomas, it does not appear to be necessary in pediatric low-grade gliomas but does contribute to pediatric high-grade gliomas. In pediatric high-grade gliomas, ALT and increased TERT expression associated with promoter hypermethylation have been observed.
Understanding differences in pediatric and adult diffuse gliomas may ultimately allow for increased prognostic precision and targeted intervention. Current therapies in development include WEE-1 inhibition for gliomas with SETD2 or G34R/V mutation, demethylase and deacetylase inhibitors for K27M mutant gliomas, PI3K/mTOR inhibitors for G34R/V mutant gliomas, telomerase inhibitors for gliomas with TERT promoter mutation, and ATR inhibitors for gliomas with ALT.
